We evaluated the contribution of patient-specific clinical and genetic factors to statin-related muscle toxicity (SRM) without a significant creatine kinase elevation (125 cases related to simvastatin or atorvastatin and 481 controls). The association between 12 single nucleotide polymorphisms (SNPs) in nine candidate genes and clinical factors with SRM was evaluated. Of the 12 SNPs genotyped, only rs4149056 in SLCO1B1 was associated with SRM in univariate analysis (with any statin, odd ratio (OR) 5 1.73, 95% confidence interval (CI) 5 1.14-2.62, P 5 0.010) and this association was influenced by sex (P 5 0.006) and BMI (P 5 0.02). In multivariate and binary logistic regression analyses, SLCO1B1 rs4149056 genotype (OR 5 1.66, 95% CI: 1.08-2.54, P 5 0.014) and sex (OR 5 1.72, 95% CI 5 1.15-2.59, P 5 0.006) were independently associated with muscle toxicity related to statin treatment. Patient-specific genetic and clinical factors associated with increased systemic exposure to statins are implicated in the full spectrum of SRM, including myalgia in addition to severe myopathy.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? þ The existence of an association between SLCO1B1 rs4149056 and simvastatin-induced myopathy has been demonstrated only at higher drug doses and when CK elevation is included in the definition of statin-associated musculoskeletal symptoms.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ Are statin-associated muscle symptoms without significantly raised CK levels caused by statins or are they a nocebo effect?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE þ Patient-specific genetic and clinical factors associated with increased systemic exposure to statins are implicated in the full spectrum of SRM, from myalgia to severe myopathy. HOW THIS MIGHT CHANGE CLINICAL PHARMA-COLOGY OR TRANSLATIONAL SCIENCE þ Pharmacological mechanisms contribute to the full spectrum of SRM, including myalgia without CK elevation. A wider understanding of the predisposing factors to SRM will enable clinicians to optimize management while minimizing untoward effects in susceptible patients.
Although statins are generally well tolerated, statin-associated side effects are a common problem in routine clinical practice, leading to dose reduction, nonadherence, or discontinuation of therapy, with consequent poor control of LDL-cholesterol and increased risk of preventable cardiovascular morbidity and mortality. 1 Statin-associated musculoskeletal symptoms (SAMS) without significant elevation of creatine kinase is the most common adverse event leading to discontinuation of therapy. 2 However, therapy can be restored in the majority of statin-intolerant patients when rechallenged. 3 Indeed, in large clinical trials minor muscle symptoms occur at a similar frequency, regardless of allocation to statin or placebo, suggesting that in most patients SAMS are not of pharmacological origin. 4, 5 Conversely, true statin-related muscle toxicity (SRM), with characteristic symptoms that resolve quickly on discontinuation of therapy and recur with rechallenge, is demonstrated in only a minority of SAMS cases under double-blind conditions. 6, 7 The phenotype of SRM ranges from tolerable myalgia to intolerable muscle pain and weakness with elevation of creatine kinase (CK) due to breakdown of muscle tissue mandating immediate withdrawal of statin therapy. 8 The graded classification proposed by Alfirevic et al. 8 defined this spectrum on a scale of 0-6 according to the severity of symptoms, CK elevation, and end organ damage. Although more severe forms of muscle toxicity, such as myopathy and rhabdomyolysis (SRM4-5), are infrequent even at higher statin doses, 8, 9 clinicians considering rechallenge in patients intolerant of the high-intensity statin regimes recommended for effective cardiovascular prevention face a difficult decision-how to distinguish patients with minor muscle symptoms of nonpharmacological origin from those with "true SRM" of moderate severity (SRM 2-3) who are at risk of progression to more severe myopathy, and in whom the high cost, nonstatin alternative therapies such as PSCK9 inhibitors may be justified.
There is consistent evidence that patient-specific clinical factors, such as advanced age, 10 female sex, 11, 12 low body mass, 13 hepatic and renal dysfunction, 14 and drug-drug interactions, 15 contribute to SRM. 16 There is also compelling evidence that genetic factors, including those that influence statin disposition and localization in skeletal muscle increase the risk of SRM in susceptible individuals. 16 The best genetic predictor for severe forms of statin-related myopathy is the rs4149056 polymorphism in the SLCO1B1 gene, which codes for the organic aniontransporting polypeptide OATP1B1. 9 The existence of an association between SLCO1B1 rs4149056 and simvastatin-induced myopathy has a well-established pharmacokinetic basis 17 and has been confirmed in clinical studies by several investigators [18] [19] [20] [21] but is clearly demonstrated only at higher doses and when CK elevation is included in the definition of SRM, 18, 22 but not at lower doses of statins or milder SRM. 23 It is less clear whether this genetic variant is a useful predictor of SRM with atorvastatin, the most widely prescribed high-potency statin. 24 However, the association between statin use and myopathy is a class effect and if less severe SRM is pharmacological in origin, an association might be expected with common variants in SLCO1B1 or other genes related to statin disposition and muscle exposure, including those involved in drug metabolism and muscle membrane transport. 25, 26 Thus, the possible contributions of common SNPs in a selection of these genes, together with patient-specific clinical factors, were evaluated in patients treated with the highest recommended doses of simvastatin and atorvastatin in a lipid clinic-based case-control study, designed to include the less severe end of the SRM spectrum (SRM2), which most commonly accounts for discontinuation of therapy in routine practice. 8 
RESULTS

Characteristics of study subjects
A total of 606 patients (125 cases and 481 controls), all of whom were of self-reported European ancestry were recruited into the study. The demographic and clinical characteristics of the study cohorts are summarized in Table 1 . All cases reported myalgia without significant CK elevation (>4 times upper limit of normal (ULN)) and were classified as SRM2. One case deteriorated to SRM4 (severe myopathy) but was later diagnosed with polymyositis, not statin-related, and was therefore excluded from the data analysis. In the case group there was a significantly greater proportion of females than the control group (58.4% vs. 44.1%; P 5 0.004). A greater proportion of patients in both the case and the control groups were treated with simvastatin than atorvastatin (107 of 125, 85.6% and 297 of 481, 61.7%, respectively; P < 0.001). In both groups, simvastatin 40 mg/day was the most frequently prescribed, while the most common dosage regimen for atorvastatin was 80 mg/day ( [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] and the controls (median 24 months, interquartile range 12-65). There was no significant association between SRM and the presence of comorbidities reported to enhance the risk of SRM, such as type 2 diabetes, impaired renal function, hypothyroidism, and hypertension. Approximately 17-30% of the cases and of controls reported concurrent exposure to drugs which have the potential to interact with the pharmacokinetics of statins, including fibrates, calcium antagonists, and CYP3A4 inhibitors. However, with the exception of warfarin (fewer patients in the case group; P 5 0.008) and dihydropyridine calcium antagonists (fewer patients in the control group; P 5 0.031) the patient-reported use of such agents was similar in cases compared to the controls. A list of all concomitant medications deemed to interact with statins which were taken by the study patients is provided in the Supplementary Table S1 . Compared to the control subjects, cases had higher concentrations of serum lipids at the time of recruitment, on maximum tolerated lipid lowering therapy, which were well above recommended treatment goals for highrisk primary and secondary prevention ( Table 1) .
Environment-gene association with SRM
The genotype frequencies of all tested SNPs were checked for their consistency with Hardy-Weinberg Equilibrium (HWE) ( Table 2) . Frequencies for one SNP, rs1050450 in GPX1, were not in HWE and this SNP was not studied further. Of the remaining 12 SNPs studied, none were significantly different to the frequencies reported in the GBR (British in England and Scotland) derived from the 1000 genomes browser (http:// browser.1000genomes.org/index.html) and met the analysis criteria of having a minor allele frequency >0.01. Subsequently, these 12 SNPs were included in further analyses. All SNPs were successfully genotyped in 99.2% of the patients (blood samples were missing for five individuals belonging to the control group). When these 12 SNPs were tested in dominant models ( Table 2) in a univariate analysis, only the SNP in SLCO1B1 (rs4149056, (c.521T>C; V174A)) was associated with SRM (P 5 0.010). There was a significantly higher proportion of carriers of the minor C allele (heterozygotes and homozygotes) in the case group, irrespective of the type of statin used, compared to the controls; 37.6% vs. 25.8% ( Figure 1a ) with odds ratio (OR) of 1.73 (95% CI: 1.14-2.62). There was no significant difference in the frequency of C allele carriers between the simvastatin and atorvastatin intolerant cases ( Figure 1b) . Polymorphisms in other genes, including SNPs in previously proposed gene candidates for SRM, i.e., GATM (rs9806699) and COQ2 (rs4693075), showed no significant difference between cases and controls.
In multivariate logistic regression analyses adjusted for patient age, sex, BMI, and the 11 remaining genotypes, SLCO1B1 rs4149056 (OR 5 1.72, 95% CI: 1.15-2.59; P 5 0.014) and female sex (OR 5 1.72 (95% CI 5 1.15-2.59; P 5 0.006)) were the only variables that were independently associated with SRM ( Table 3 ). In the statin-intolerant group the relative risk of SRM Table 2 Continued on next page ARTICLE was higher in females and it increased further in patients with C variant allele irrespective of sex ( Table 4 ). In the C allele carriers, the BMI was significantly lower in the cases (N 5 47, mean BMI 27.9 kg/m 2 ) than the controls (N 5 123, mean BMI 29.8 kg/m 2 ) a mean difference in BMI of 1.9 kg/m 2 (P 5 0.02). According to binary logistic regression analysis, only sex (P 5 0.004), SLCO1B1 genotype (P 5 0.011), and logged BMI in C allele carriers (P 5 0.014) were found to be significantly associated with SRM.
DISCUSSION
A modern dilemma faced by clinicians who prescribe statins is how to decide which, if any, patients with muscle symptoms in the absence of significant CK elevation have "true" statin-related muscle toxicity (SRM), related to the pharmacology of statins, and which have nonspecific musculoskeletal symptoms reflecting a high background prevalence in patients eligible for statin treatment. In order to determine whether pharmacological factors contribute to less severe statin-related muscle toxicity in patients referred to a specialist lipid clinic, we examined the association between SRM2-3 defined by dechallenge and rechallenge, and polymorphisms in candidate genes implicated in statin disposition and safety alongside patient demographics and clinical features. Our findings of a clear association between SRM2 and both the SLCO1B1 rs4149056 polymorphism and sex is consistent with findings reported previously in both moderate and severe cases 9, 15, 18 which provides further evidence indicating that SRM of moderate severity is, at least in part, of pharmacological origin and appears related to altered systemic and muscular drug exposure. Therefore, the symptoms reported by patients with moderate SRM, as defined in our cohort, cannot be attributed solely to a "nocebo effect" or misattribution of symptoms, and imply that tailored strategies for lipid lowering therapy may reduce the risk of SRM.
Our findings of the association between female sex and SRM is in concordance with previous findings from clinical trials 9, 18 and epidemiological studies reporting that, female sex (linked to small body frame), along with patient age and frailty, increase susceptibility to SRM. 27 In the entire study cohort, we found no association between patient age and BMI and SRM; however, the SLCO1B1 C allele carriers in the case group, irrespective of age, had a significantly lower BMI. Our data supports the view that low BMI is an endogenous risk factor for SRM, 2,28 perhaps because low BMI, which is linked to smaller vascular volumes and reduced muscle mass, could lead to greater statin systemic exposure, thus exacerbating the risk of SRM, particularly in the C allele carriers.
Systemic exposure to statins appears to be attributable, to an extent, to the SLCO1B1 rs41490565 polymorphism, resulting in altered hepatic drug uptake. It has been demonstrated that, relative to the wildtype TT genotype, homozygosity for the C allele increases the area under the plasma concentration vs. time (AUC) by 221% for active simvastatin acid, 29 significantly more than for other statins, including pitavastatin (162-191%), atorvastatin (144%), pravastatin (57-130%), rosuvastatin (62-117%), and least for fluvastatin (19%). 15 Although previous studies have shown conflicting results on the susceptibility to SRM with other statins, 11, 18, 20, 21, 30 there may be an increased risk for SRM among Genotype results for all the SNPs investigated were unavailable for five individuals from control group. SLCO1B1 rs4149056 carriers using atorvastatin, as suggested by Pasanen et al. 31 Whether SLCO1B1 rs4149056 truly confers susceptibility among atorvastatin-intolerant cases remains inconclusive, but the effects of the variant on the pharmacokinetics of atorvastatin 31 are certainly smaller than seen with simvastatin.
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It is also known that hepatic uptake of atorvastatin is mediated not only by OATP1B1 but also by OATP1B3 33 and atorvastatin and its lactone appears to have lesser inhibitory effect on mitochondrial complex III activity. 34 In the present study, we found no evidence of contributions from any of the newly proposed candidate genes toward SRM. Surprisingly, we found no association between CYP3A4*22 and SRM, even though the SNP rs35599367 has been associated with reduced CYP3A4 activity, which is involved in the metabolism of both simvastatin and atorvastatin and has been previously demonstrated to contribute to variability in simvastatin efficacy in the Dutch population. 35 In our study, patients were identified as SRM cases on the basis of having received either simvastatin or atorvastatin and discontinued treatment because of intolerable muscle symptoms which later resolved on drug withdrawal and recurred on rechallenge, without a significant increase in CK. As the statin rechallenge was unblinded and often undertaken prior to referral, we expect that a proportion of cases who failed rechallenge without CK elevation did not have true SRM, as has been demonstrated by double-blind rechallenge with statins. 7 While measurement of CK is recommended as a biomarker of muscle damage in symptomatic patients 9, 14, 36 and is important for classifying SRM according to severity, it is nonspecific and cannot be used alone for establishing SRM. Since CK levels during initial exposure were frequently unavailable (at the time of recruitment the majority of cases had already stopped statin therapy), we cannot exclude the possibility that the severity grading in some of our patients may have been underestimated, potentially misclassifying SRM3 or even SRM4 cases as SRM2. However, this is also likely to reflect the situation in clinic practice and although challenging, prompt measurement of CK in symptomatic patients remains of central importance for the clinical assessment of SRM.
Our study suggests that, among people of European ancestry, SLCO1B1 rs4149056 is a predisposing factor for SRM across the full spectrum of severity (SRM2 or greater) with simvastatin and atorvastatin at the highest recommended dose (40 mg and 80 mg, respectively). It has been proposed that the SLCO1B1 rs4149056 polymorphism may help identify patients at risk of progression to more severe statin-related myopathy. For simvastatin users, possession of the C allele had a diagnostic sensitivity and specificity of 70.4% and 73.7%, respectively, giving positive and negative likelihood ratios of 2.7 and 0.4 for the prediction of definite or incipient myopathy during 5 years of 80 mg/day simvastatin use. 37 However, in view of the low positive predictive value for progression to severe Odds ratio describes the odds to be a case relative to a control when having at least one variant allele (or being female). myopathy and high frequency of the C allele in statin-tolerant patients, in our opinion the possession of the C allele is not a clinically useful diagnostic test to identify patients at risk of SRM.
In conclusion, our results demonstrate that symptoms reported by patients with SRM of moderate severity are, at least in part, of pharmacological origin and cannot be attributed solely to a "nocebo effect." SLCO1B1 rs4149056 genotype is an important susceptibility factor which, together with female gender, is associated with the full spectrum of SRM seen in patients treated with high doses of simvastatin and atorvastatin. However, we found no association between SRM and polymorphisms in any of the newly proposed gene candidates studied, and an accurate, predictive diagnostic test for susceptibility to SRM remains elusive. In view of their proven safety and low cost, statins will remain in clinical use for the foreseeable future. Therefore, in order to improve the already overwhelmingly positive benefit-risk ratio of statins, clinicians must adopt a pragmatic approach to reduce the risk of SRM when prescribing statins, where possible avoiding the use of simvastatin, which has the greatest potential for toxicity, by choosing lower initiation doses in women and other patients with lower body mass index and by avoiding coadministration of potentially interacting drugs. Patients who had previously received either simvastatin 40 mg or atorvastatin 80 mg but had discontinued the drug because of new muscle symptoms (intolerable muscle pain or weakness, with or without elevation of creatine kinase, onset within 6 months of starting therapy), which resolved on withdrawal and recurred with rechallenge at the same or a reduced dose were considered to have SRM and to be eligible for recruitment as cases. In each case the severity of muscle toxicity was graded according to the classification system based on the severity of musclerelated symptoms (tolerable or intolerable) and the CK elevation (less than four times the ULN in SRM2) proposed by Alfirevic et al. 8 The local laboratory reference ranges for creatine kinase were as follows: Male 10-190 U/L; Female 10-160 U/L.
After obtaining informed written consent, the medical records of those previously intolerant of simvastatin and/or atorvastatin were reviewed and a structured face-to-face interview was conducted by a trained research nurse. Patient demographics (including age, sex, height, and weight), comorbidities, and medications were recorded. The indication for statin therapy, the daily doses and type of statins used, and the regional distribution and temporal pattern of symptoms of muscle pain or weakness were recorded. In addition to routine serum biochemical measurements, each patient provided a venous blood sample (4 ml) which was transferred into EDTA tubes and stored at -808C for later genotyping.
SNP selection, DNA extraction, and genotyping SNPs of known functional significance were selected based on previous findings. 9, 11, [38] [39] [40] [41] [42] Additionally, rs1050450 and rs713041 in glutathione peroxidases 1 and 4 (GPX1 and GPX4), respectively, were selected on the basis of decreased GPX activity associated with these SNPs reported by several previous studies [43] [44] [45] [46] [47] (Table 5) . While there is evidence for the involvement of OATP2B1 and various multidrug resistanceassociated proteins (MRPs) in transport of statins in striated muscle, 48 there is no information available on the involvement of monocarboxylate transporters (MCTs), which are abundantly expressed in the skeletal muscle, and their polymorphisms in relation to SRM. We hypothesized that SRM could be promoted by the increased uptake of statins and/or accumulation of endogenous monocarboxylate metabolites (e.g., lactate) in skeletal muscle which mainly involve MCTs, possibly MCT1 and MCT4. 25, 26 Since there was no prior information available on the influence of either MCT1 (SLC16A1) or MCT4 (SLC16A3) gene on statin-related myopathy, tag-SNP selection was employed for these two genes ( Table 6) , with tag-SNPs in both MCT1 and MCT4 selected from the HapMap website (http://www.hapmap.org). The data from the tagging approach from the HapMap website captured 100% of alleles, with mean r 2 0.994 and 1.0, for the SLC16A1 and SLC16A3 genes, respectively. DNA extraction and genotyping DNA extraction was carried out using perchloric the acid-chloroform extraction method as described by Daly et al. 49 Most SNPs were genotyped by TaqMan assays designed and supplied by Applied Biosystems in an ABI StepOne Real Time PCR system (Paisley, UK) under the following thermocycling conditions: 10 min at 958C followed by 40 cycles of denaturation at 958C for 15 sec and annealing/extension at 608C for 1 min. Genotypes for polymorphisms in ABCC2 (rs717620) and ABCG2 (rs2231142) together with one SNP in SLC16A1 (rs1049434) were determined by PCR-RFLP 50 using the conditions summarized in Table 6 .
Sample size calculation
Assuming an rs4149056 SLCO1B1 minor allele frequency of 0.14 in our statin-tolerant patients, we calculated that a sample size of 600 patients (500 controls and 100 cases) with 85% power would detect an OR of 2 at a significance value of 0.05. We hypothesized that a multitude of other factors contribute to intolerance to simvastatin and atorvastatin, including clinical and environmental factors and common variants in the genes that mediate statin systemic exposure. However, as there is no a priori information available on the variance in drug exposure (plasma simvastatin/atorvastatin concentration), and the quantitative effect of each genetic variant and other confounders including patient characteristics on the risk of statin muscle toxicity, we considered this sample size to be sufficient to detect any association of comparable magnitude.
Statistical analysis
Statistical analyses for all clinical parameters (expressed as mean, SD, 95% CI) were performed using Minitab statistical software (v. 16, Coventry, UK). For univariate analysis, chi-square statistics were used for categorical variables and t-tests for continuous variables. Where necessary, data were log-transformed to achieve normality. For multivariate analysis, by taking a dichotomous variable (cases vs. controls) as dependent variable, binary logistic regression was performed to assess independent patient, clinical, and genetic risk factor/s associated with the cases. Comparison of genotype frequencies for one or two variant alleles between cases vs. controls was made using binary logistic regression; the Hosmer and Lemeshow goodness-of-fit test was used as an indicator of the validity at the last step of iterations. A dominant model for genotypes (i.e., wildtype vs. (heterozygous 1 homozygous genotype)) was used for all SNPs studied due to homozygous mutants being rare. For all analyses, P < 0.05 was taken as being statistically significant.
Additional Supporting Information may be found online in the supporting information tab for this article. Apart from the annealing temperatures described above, all PCR assays involved 35 cycles, with denaturation at 94 8C for 1 min, extension at 72 C for 1 min and were held in the last cycle at 72 C for 7 min to ensure elongation except for rs2231142. For rs2231142, the period for each step in each cycle was 35 sec instead of 1 min. The ABCG2 and SLC16A1 assays were developed for this project. The ABCC2 assay was described previously (42) .
